Form 4: Pacira BioSciences Executive Acquires Shares and Stock Options

Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, reports acquisition of common stock and stock options.

Summary

• On February 1, 2025, Brendan Teehan, Chief Commercial Officer of Pacira BioSciences, acquired 54,000 shares of common stock.
• These shares were acquired at a price of $0.
• Following this transaction, Teehan directly owns 54,000 shares of Pacira BioSciences.
• On February 4, 2025, Teehan also acquired 99,500 stock options with an exercise price of $26.59, exercisable beginning February 4, 2026, and expiring on February 4, 2036.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports factual information about executive compensation.

Positives

• The acquisition of shares and stock options by a key executive could be interpreted as a positive signal regarding the executive's confidence in the company's future prospects.

Future Outlook

The restricted stock units vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. The stock options vest and become exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Industry Context

Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders. This Form 4 filing is a routine disclosure of such compensation.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules and exercise prices are generally structured to reward long-term performance and retention.

Stakeholder Impact

• Shareholders may view the executive's acquisition of shares and options as a sign of confidence in the company's future.
• Employees may be motivated by the alignment of executive incentives with company performance.

Key Dates

Keywords

Pacira BioSciences, Brendan Teehan, stock options, common stock, acquisition, Form 4, executive compensation